BLU-782 is primarily investigated for its potential therapeutic applications in the treatment of various cancers. It functions as a selective inhibitor of fibroblast growth factor receptor (FGFR), which plays a critical role in cell proliferation, survival, and differentiation. By targeting FGFR, BLU-782 aims to disrupt signaling pathways that are often dysregulated in cancer cells, particularly in tumors with FGFR alterations or amplifications. This makes it a promising candidate for precision medicine approaches in oncology, especially for patients with FGFR-driven cancers such as bladder cancer, cholangiocarcinoma, and certain types of breast and lung cancers. Ongoing clinical trials are evaluating its efficacy, safety, and potential as a targeted therapy in these indications.